Market Overview

MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akers Biosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Share:

The
Schall Law Firm
, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Akers
Biosciences, Inc. ("Akers" or ''the Company'') (NASDAQ: AKER)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.

Investors who purchased the Company's shares between May 15, 2017, and
June 5, 2018, inclusive (the ''Class Period''), are encouraged to
contact the firm before August 13, 2018.

If you are a shareholder who suffered a loss, click
here to participate
.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm's website at www.schallfirm.com,
or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading
statements to the market throughout the class period. Akers improperly
recognized revenue for the year ending December 2017. Akers did not
disclose the extent of the weakness of the Company's internal controls
over financial reporting. This resulted in the Company making materially
false and misleading public statements. According to the lawsuit, when
accurate information about Akers became apparent in the market,
investors suffered damages. The Schall Law Firm represents investors
around the world and specializes in securities class action lawsuits and
shareholder rights litigation.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.

View Comments and Join the Discussion!